Bristol-Myers Squibb Company (NYSE:BMY) is one of the 25 stocks Jim Cramer recently shared insights on. While discussing drug stocks, Cramer mentioned BMY and said: “Of course, some of the rally’s ...

Cigna claims Bristol Myers’ Celgene unit filed sham lawsuits it knew it was unlikely to win in an effort to protect its ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

Bristol Myers Squibb (BMY) closed the most recent trading day at $47.51, moving +2.64% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 0.11%. On the ...

Bristol Myers Squibb to cut 68 jobs in Lawrenceville as part of a broader restructuring effort aiming to slash $2B in costs ...

Amgen acquired Five Prime in 2021 on the back of the phase 2 FIGHT trial of bemarituzumab, which achieved significant ...

On Tuesday, Citi downgraded Prime Medicine Inc. (NASDAQ:PRME) from a Buy to a Neutral rating while also significantly reducing its price target from $10 to $1.50.

Despite hitting a clinical “milestone,” Prime Medicine is shelving its sole clinical-stage genetic medicine. The Cambridge, Massachusetts-based biotech is also laying off staffers and CEO ...

Executive elevations: Editas Medicine elevated SVP of finance Amy Parison to CFO. Skye Bioscience promoted Tu Diep to chief operating officer from chief development officer. Allison Emery was promoted ...

In Tanzania, Texas Children’s Global HOPE Program and Baylor College of Medicine Global Health, backed by funding from the Bristol Myers Squibb Foundation, will collaborate with Baylor College of ...

Reports Q3 revenue $209K, consensus $7.83M…In September 2024, Prime Medicine (PRME) entered into a strategic research collaboration and license agreement with Bristol Myers Squibb to develop and ...